what are real-life Challenges in implementing new therapeutics in mRCC management?
In this second episode of mRCC DoctoLIVE series, we will be questioning what are challenges in implementing new therapeutics in metastatic renal cell carcinoma in 2022.
Fill in the form below if you are interested in attending our next DoctoLIVE - Episode 2: mRCC US Live Session, and we will send you event's details.
You can also submit your own questions, we will incorporate them into the live discussion.
EPISODE 2
mRCC US Live session
Monday 11th of April 2022
at 5PM CEST / 11AM ET / 8AM PT / 4PM BST
Our guest is Dr. Arnab BASU, an academic genitourinary oncologist from UAB hospital, experienced in the use of immunotherapy and targeted therapies, with research interests in improving immunotherapies in Bladder Cancer.
Interviewed by Karen HIGGINBOTTOM from our APLUSA Bell Falla
DoctoLIVE: A new opportunity to get answers to your questions directly from actual practitioners, all organized by APLUSA
Why DoctoLIVE? 15 minutes of an HCP’s time booked by APLUSA to answer your practical questions, live.
DoctoLIVE is your window to real-world challenges in real-life healthcare practice, from an actual healthcare practioner's perspective.
DoctoLIVE offers you a 15-minute open-mic discussion featuring a different HCP every session, answering your questions related to real-life treatment experiences. These discussions will be held in English.
We will cover how to implement new therapeutics in actual practice, uncover pain points and discuss areas for improvement.